# US 2016/0354340 A1 · Lipoic acid choline ester compositions and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354340 A1
- Document ID: US20160354340A1
- Status: Published application
- Kind: A1
- Application number: 15/118,910
- Filed: 2015-03-03
- Published: 2016-12-08
- Earliest claimed: 2014-03-03
- Assignees: Encore Vision Inc.
- Applicants: Encore Vision Inc.
- Inventors: William H. GARNER; Margaret H. GARNER; William R. BURNS
- Web page: https://patentgrep.com/patent/US20160354340A1

## CPC

- A61K 31/385: having two or more sulfur atoms in the same ring
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/186: {Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide}
- A61P 27/02: Ophthalmic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are pharmaceutical compositions comprising a therapeutically effective amount of lipoic acid choline ester or derivatives thereof and a non-aqueous excipient mixed in an aqueous solution. Also provided herein are non-aqueous compositions prepared by mixing the therapeutically effective amount of lipoic acid choline ester and the non-aqueous excipient. The non-aqueous compositions can be further mixed with the aqueous solution.

## Claims

### Claim 1

A pharmaceutical composition comprising a therapeutically effective amount of lipoic acid choline ester and a non-aqueous excipient, mixed in an aqueous solution having a pH of 4 to 6, wherein at least 95% of the lipoic acid choline ester is present in the pharmaceutical composition, as measured by HPLC, following storage at 25° C. under 40% relative humidity for 3 months.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein less than 2% of the lipoic acid choline ester is degraded following storage at 25° C. under 40% relative humidity for 3 months.

### Claim 3 (depends on 1, 2)

The pharmaceutical composition of claim 1 or claim 2, having less than 12% total drug related impurities based on area-under-the-curve as determined by HPLC following storage at 25° C. under 40% relative humidity for 3 months.

### Claim 4 (depends on 1, 2, 3)

The pharmaceutical composition of any of claims 1-3, having less than 7% of a drug related impurity based on area-under-the-curve as determined by HPLC following storage at 25° C. under 40% relative humidity for 3 months, wherein the drug related impurity is characterized by a relative retention time of 1.12 to 1.14.

### Claim 5 (depends on 1, 2, 3, 4)

The pharmaceutical composition of any of claims 1-4, having less than 4% of a drug related impurity based on area-under-the-curve as determined by HPLC following storage at 25° C. under 40% relative humidity for 3 months, wherein the drug related impurity is characterized by a relative retention time of 0.65 to 0.66.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The pharmaceutical composition of any of claims 1-5, characterized by one or more of the following:
(a) having a concentration of the lipoic acid choline ester of 1% to 10% by weight of the composition;
(b) having a concentration of a preservative of 0.005% to 0.1% by weight of the composition;
(c) having a biochemical energy source of 0.1% to 5% by weight of the composition; and
(d) having a concentration of glycerol of 0.5% to 5% by weight of the composition.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, wherein the preservative is benzalkonium chloride and the biochemical energy source is alanine.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The pharmaceutical composition of any of claims 1-7, wherein the lipoic acid choline ester has a counter ion selected from the group consisting of chloride, bromide, iodide, sulfate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, hydrogen fumarate, tartrate, succinate, benzoate, and anion of glutamic acid.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A method of improving accommodative amplitude in a lens, comprising administering to the lens an effective amount of the pharmaceutical composition of any of claims 1-8.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A method of treating or preventing presbyopia in a subject, comprising administering to an eye of the subject an effective amount of the pharmaceutical composition of any of claims 1-8.

### Claim 11

A non-aqueous composition comprising lipoic acid choline ester or derivatives thereof and a non-aqueous excipient.

### Claim 12 (depends on 11)

The non-aqueous composition of claim 11, wherein the non-aqueous excipient is substantially miscible with water.

### Claim 13 (depends on 11, 12)

The non-aqueous composition of claim 11 or claim 12, wherein the non-aqueous excipient is a non-hydrolytic solvent.

### Claim 14 (depends on 11, 12, 13)

The non-aqueous composition of any of claims 11-13, wherein the non-aqueous excipient is an alcohol.

### Claim 15 (depends on 14)

The non-aqueous composition of claim 14, wherein the alcohol is a polyol.

### Claim 16 (depends on 15)

The non-aqueous composition of claim 15, wherein the polyol is glycerol.

### Claim 17 (depends on 15)

The non-aqueous composition of claim 15, wherein the polyol is propylene glycol.

### Claim 18 (depends on 11)

The non-aqueous composition of claim 11, wherein the non-aqueous excipient is a semifluorinated alkane.

### Claim 19 (depends on 11, 12, 13, 14, 15, 16, 17, 18)

The non-aqueous composition of any of claims 11-18, comprising a non-aqueous solution obtained by mixing lipoic acid choline ester with the non-aqueous excipient.

### Claim 20 (depends on 19)

The non-aqueous composition of claim 19, wherein the mixing is conducted at a temperature of 20° C. to 100° C.

### Claim 21 (depends on 20)

The non-aqueous composition of claim 20, wherein the mixing is conducted at a temperature of 37° C. to 80° C.

### Claim 22 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The non-aqueous composition of any of claims 11-21, wherein the concentration of lipoic acid choline ester or derivatives thereof is in a range of 0.1% to 40% by weight of the composition.

### Claim 23 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The non-aqueous composition of any of claims 11-22, wherein the lipoic acid choline ester has a counter ion selected from the group consisting of chloride, bromide, iodide, sulfate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, hydrogen fumarate, tartrate, succinate, benzoate, and anion of glutamic acid.

### Claim 24 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

An ophthalmic formulation comprising the non-aqueous composition of any of claims 11-23 mixed in an aqueous solution.

### Claim 25 (depends on 24)

The ophthalmic formulation of claim 24, wherein the aqueous solution comprises a buffer.

### Claim 26 (depends on 24, 25)

The ophthalmic formulation of claim 24 or claim 25, having a pH of 4 to 8.

### Claim 27 (depends on 26)

The ophthalmic formulation of claim 26, having a pH of 4.5.

### Claim 28 (depends on 24, 25, 26, 27)

The ophthalmic formulation of any of claims 24-27, comprising at least one ingredient selected from the group consisting of a biochemically acceptable energy source, a preservative, a buffer agent, a tonicity agent, a surfactant, a viscosity modifying agent, and an antioxidant.

### Claim 29 (depends on 24, 25, 26, 27, 28)

The ophthalmic formulation of any of claims 24-28, wherein the non-aqueous composition is sterilized before mixing in the aqueous solution.

### Claim 30 (depends on 24, 25, 26, 27, 28, 29)

The ophthalmic formulation of any of claims 24-29, wherein the aqueous solution is a sterilized solution.

### Claim 31 (depends on 24, 25, 26, 27, 28, 29, 30)

The ophthalmic formulation of any of claims 24-30, characterized by one or more of:
(a) having a concentration of the lipoic acid choline ester or derivatives thereof from 1% to 10% by weight of the formulation;
(b) having a concentration of a preservative 0.005% to 0.1% by weight of the formulation;
(c) having a pH of 4 to 6;
(d) having a biochemical energy source of 0.1% to 5% by weight of the formulation;
(e) having a concentration of glycerol of 0.5% to 5% by weight of the formulation; and
(f) having a shelf-life stability of greater than 3 months.

### Claim 32 (depends on 31)

The ophthalmic formulation of claim 31, wherein the preservative is benzalkonium chloride and the biochemical energy source is alanine.

### Claim 33 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

A method of improving accommodative amplitude in a lens, comprising administering to the lens an effective amount of the non-aqueous composition of any of claims 11-23 or the ophthalmic formulation of any of claims 24-32.

### Claim 34 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

A method of treating or preventing presbyopia in a subject, comprising administering to an eye of the subject an effective amount of the pharmaceutical composition of any of claims 11-23 or the ophthalmic formulation of any of claims 24-32.

### Claim 35

A system comprising a first compartment, a second compartment, and a seal separating the first and second compartments, wherein the first compartment comprises a non-aqueous composition of an active ingredient and a non-aqueous excipient, the second compartment comprises an aqueous solution, and wherein the system is activated upon breaking the seal and mixing the non-aqueous solution with the aqueous solution.

### Claim 36 (depends on 35)

The system of claim 35, wherein the active ingredient is lipoic acid choline ester or derivatives thereof and the non-aqueous excipient is an ophthalmically acceptable excipient.

### Claim 37 (depends on 35, 36)

The system of claim 35 or claim 36, wherein the aqueous solution comprises a buffer.

### Claim 38 (depends on 35, 36, 37)

The system of any of claims 35-37, wherein both the non-aqueous composition and the aqueous solution are sterilized.

### Claim 39 (depends on 35, 36, 37, 38)

The system of any of claims 35-38, wherein the active ingredient in the system has a shelf-stability of more than 3 months.

### Claim 40 (depends on 39)

The system of claim 39, wherein the active ingredient in the system has a shelf-stability of more than 6 months.

### Claim 41 (depends on 35, 36, 37, 38, 39, 40)

The system of any of claims 35-40, wherein the active ingredient in the system after activation has a shelf-stability of more than 3 months.

### Claim 42

A method of storing an active ingredient that is susceptible to hydrolysis in an aqueous solution, the method comprising (a) providing the active ingredient in a first compartment; (b) providing the aqueous solution in a second compartment; and (c) separating the first and second compartments with a seal, wherein the active ingredient in the first compartment is not in contact with the aqueous solution until just prior to usage by breaking the seal.

### Claim 43 (depends on 42)

The method of claim 42, wherein the active ingredient in the first compartment is a lyophilized powder or is mixed with a non-hydrolytic solvent.

### Claim 44 (depends on 42, 43)

The method of claim 42 or 43, wherein the active ingredient is lipoic acid choline ester or derivatives thereof, or a peptide.
